2023
DOI: 10.1111/jdv.18843
|View full text |Cite
|
Sign up to set email alerts
|

Long‐term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial

Abstract: Background Primary axillary hyperhidrosis (PAHH) strongly affects the patient's quality of life. To date, topical treatment options are limited. One percent glycopyrronium bromide (GPB) showed promising efficacy and safety in a pivotal 4‐week Phase 3a study. Objectives To assess efficacy and safety of topical 1% GPB cream in patients with severe PAHH in a long‐term study of 72 weeks versus baseline. Methods This was a long‐term, open‐label, Phase 3b trial for 72 weeks including 518 patients with severe PAHH. P… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 9 publications
references
References 24 publications
0
0
0
Order By: Relevance